Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Pulmonx Corp publishes a filing, an earnings call transcript or a press release.

Get LUNG alerts

About Derrick Sung

Derrick Sung is recorded as COO at Pulmonx Corp (LUNG) since November 3, 2025 and CFO at Pulmonx Corp (LUNG). The newest filing on record that lists Derrick Sung as CFO at Pulmonx Corp (LUNG) is dated April 22, 2026. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Derrick Sung was appointed Chief Operating Officer and Chief Financial Officer, effective November 3, 2025. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Derrick Sung was appointed Chief Operating Officer and Chief Financial Officer, effective November 3, 2025. Pulmonx Corp reported in an 8-K filed October 10, 2023 that Derrick Sung resigned as Chief Financial Officer, effective October 10, 2023. The proxy statement of Pulmonx Corp reports total compensation of $2,951,391 for Derrick Sung in fiscal 2025, including a base salary of $83,333. Disclosed compensation is on record for 3 fiscal years. Derrick Sung has spoken on 12 earnings calls and 1 other investor event across 1 company, most recently for Pulmonx Corp on August 11, 2026. Pulmonx Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Pulmonx Corp includes Glendon E. French (CEO and Board Member), Glendon French (CEO and Board Member), Steven S. Williamson (CEO and Board Member) and 4 others.

“the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025.”
Pulmonx Corp Form 8-K, filed October 27, 2025 · Read the filing
“On October 21, 2025, the Company's Board of Directors appointed Derrick Sung, Ph.D., aged 52, as the Company's Chief Operating Officer and Chief Financial Officer as of November 3, 2025 (the "Sung Effective Date").”
Pulmonx Corp Form 8-K, filed October 27, 2025 · Read the filing

Derrick Sung on recent calls

“I'll try and step through each one of those. Let me start by saying that, you know, we're really focused on delivering what we say we're going to deliver and not getting out in front of our skis in terms of the commitments that we make, right?”
CFO, Canaccord Genuity 46th Annual Growth Conference ·
“Total worldwide revenue for the 3 months ended June 30, 2023, reached a new quarterly high of $17.2 million, a 23% increase from $14 million in the same period of the prior year.”
CFO, Pulmonx Corp Q2 FY2023 Earnings Call ·
“Total worldwide revenue for the three months ended March 31, 2023, was $14.5 million, a 35% increase from $10.8 million in the same period of the prior year and an increase of 37% on a constant currency basis.”
CFO, Pulmonx Corp Q1 FY2023 Earnings Call ·
“Total worldwide revenue for the three months ended December 31, 2022, was a record $15.4 million, a 13% increase from $13.7 million in the same period of the prior year, and an increase of 18% on a constant currency basis.”
CFO, Pulmonx Corp Q4 FY2022 Earnings Call ·
“Total worldwide revenue for the 3 months ended September 30, 2022, was $13.5 million, a 2% increase from $13.3 million in the same period of the prior year, and an increase of 7% on a constant currency basis.”
CFO, Pulmonx Corp Q3 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Pulmonx Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Pulmonx Corp (LUNG) $83,333 $2,951,391
2024 Pulmonx Corp (LUNG) — —
2023 Pulmonx Corp (LUNG) $357,500 $2,676,860

Recent activity